{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "SARS-CoV-2 endosomal infection",
      "SARS-CoV-2 mutants",
      "TMPRSS2 in viral infection",
      "lenti-Spike pseudovirus",
      "omicron functional mutants",
      "viral-mediated membrane fusion"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "37243215",
  "DateCompleted": {
    "Year": "2023",
    "Month": "05",
    "Day": "29"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "05",
    "Day": "30"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2023",
        "Month": "05",
        "Day": "09"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "1129",
      "10.3390/v15051129"
    ],
    "Journal": {
      "ISSN": "1999-4915",
      "JournalIssue": {
        "Volume": "15",
        "Issue": "5",
        "PubDate": {
          "Year": "2023",
          "Month": "May",
          "Day": "09"
        }
      },
      "Title": "Viruses",
      "ISOAbbreviation": "Viruses"
    },
    "ArticleTitle": "SARS-CoV-2 Omicron Specific Mutations Affecting Infectivity, Fusogenicity, and Partial TMPRSS2-Independency.",
    "Abstract": {
      "AbstractText": [
        "The COVID-19 pandemic resulted from the global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since its first appearance in 2019, new SARS-CoV-2 variants of concern (VOCs) have emerged frequently, changing the infection's dynamic. SARS-CoV-2 infects cells via two distinct entry routes; receptor-mediated endocytosis or membrane fusion, depending on the absence or presence of transmembrane serine protease 2 (TMPRSS2), respectively. In laboratory conditions, the Omicron SARS-CoV-2 strain inefficiently infects cells predominantly via endocytosis and is phenotypically characterized by decreased syncytia formation compared to the earlier Delta variant. Thus, it is important to characterize Omicron's unique mutations and their phenotypic manifestations. Here, by utilizing SARS-CoV-2 pseudovirions, we report that the specific Omicron Spike F375 residue decreases infectivity, and its conversion to the Delta S375 sequence significantly increases Omicron infectivity. Further, we identified that residue Y655 decreases Omicron's TMPRSS2 dependency and entry via membrane fusion. The Y655H, K764N, K856N and K969N Omicron revertant mutations, bearing the Delta variant sequence, increased the cytopathic effect of cell-cell fusion, suggesting these Omicron-specific residues reduced the severity of SARS-CoV-2. This study of the correlation of the mutational profile with the phenotypic outcome should sensitize our alertness towards emerging VOCs."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0002-1451-7065"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel."
          }
        ],
        "LastName": "Strobelt",
        "ForeName": "Romano",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel."
          }
        ],
        "LastName": "Broennimann",
        "ForeName": "Karin",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel."
          }
        ],
        "LastName": "Adler",
        "ForeName": "Julia",
        "Initials": "J"
      },
      {
        "Identifier": [
          "0000-0002-0545-6512"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel."
          }
        ],
        "LastName": "Shaul",
        "ForeName": "Yosef",
        "Initials": "Y"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Viruses",
    "NlmUniqueID": "101509722",
    "ISSNLinking": "1999-4915"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Spike Glycoprotein, Coronavirus"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "spike protein, SARS-CoV-2"
    },
    {
      "RegistryNumber": "EC 3.4.21.-",
      "NameOfSubstance": "TMPRSS2 protein, human"
    },
    {
      "RegistryNumber": "EC 3.4.21.-",
      "NameOfSubstance": "Serine Endopeptidases"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Spike Glycoprotein, Coronavirus"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Serine Endopeptidases"
    }
  ],
  "CoiStatement": "The authors declare no conflict of interest."
}